290 related articles for article (PubMed ID: 1111463)
1. Remission maintenance therapy for multiple myeloma.
Arch Intern Med; 1975 Jan; 135(1):147-52. PubMed ID: 1111463
[TBL] [Abstract][Full Text] [Related]
2. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of Kahler's disease].
Foa J; Carcassonne Y
Sem Hop; 1976 Jan; 52(3):165-71. PubMed ID: 186874
[No Abstract] [Full Text] [Related]
4. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
[TBL] [Abstract][Full Text] [Related]
5. Sequential therapy compared with combination therapy in multiple myeloma.
Arch Intern Med; 1975 Jan; 135(1):163-71. PubMed ID: 1111465
[TBL] [Abstract][Full Text] [Related]
6. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
[TBL] [Abstract][Full Text] [Related]
7. Nitrosoureas in multiple myeloma.
Salmon SE
Cancer Treat Rep; 1976 Jun; 60(6):789-94. PubMed ID: 782701
[TBL] [Abstract][Full Text] [Related]
8. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J
Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535
[TBL] [Abstract][Full Text] [Related]
9. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
[TBL] [Abstract][Full Text] [Related]
10. Treatment of plasma cell myeloma with cytotoxic agents.
Bergsagel DE; Pruzanski W
Arch Intern Med; 1975 Jan; 135(1):172-6. PubMed ID: 803363
[TBL] [Abstract][Full Text] [Related]
11. [Results with the use of the M-2 protocol in plasmacytoma].
Ho AD; Wittkamp S; Theml H; Keilholz U; Hunstein W
Dtsch Med Wochenschr; 1986 May; 111(22):858-61. PubMed ID: 3754811
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy for multiple myeloma.
Alexanian R; Salmon S; Bonnet J; Gehan E; Haut A; Weick J
Cancer; 1977 Dec; 40(6):2765-71. PubMed ID: 589554
[TBL] [Abstract][Full Text] [Related]
13. [Chemotherapy of multiple myeloma. Review of the recent trials].
Tribalto M; Arcese W; Colombo R; Pastore S; Franchii A
Recenti Prog Med; 1981 Aug; 71(2):141-7. PubMed ID: 7031807
[No Abstract] [Full Text] [Related]
14. Occurrence of multiple myeloma 13 years after Hodgkin's disease: chance or consequence?
Strobel ES; Bauchmüller K; Schmitt-Gräff A; Engelhardt M
Ann Hematol; 2005 Nov; 84(12):830-2. PubMed ID: 16132908
[No Abstract] [Full Text] [Related]
15. Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU.
Kyle RA; Gailani S; Seligman BR; Blom J; McIntyre OR; Pajak TF; Holland JF
Cancer Treat Rep; 1979 Aug; 63(8):1265-9. PubMed ID: 476704
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
Snigurowicz J; Kraj M; Rostkowska J; Maj S; Mariańska B; Mendek E; Roszkowski S; Kilian Z; Kołakowski L
Arch Immunol Ther Exp (Warsz); 1981; 29(2):145-53. PubMed ID: 7030265
[No Abstract] [Full Text] [Related]
17. The therapeutic efficacy of VBCMP-M2 protocol in multiple myeloma.
Colović MD; Janković GM; Nikolov VS; Suvajdzić ND; Miletić VD
Haematologia (Budap); 1994; 26(2):91-6. PubMed ID: 7890267
[TBL] [Abstract][Full Text] [Related]
18. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
19. [Value of successive chemotherapy in multiple myeloma of bone. Prospective study over 4 years].
Bataille R; Morlock G; Rosenberg F; Lopitaux R; Blotman F; Sany J; Ciurana AJ; Rampon S; Bussière JL; Simon L; Serre H
Rev Rhum Mal Osteoartic; 1980 Feb; 47(2):77-82. PubMed ID: 7361063
[TBL] [Abstract][Full Text] [Related]
20. [Chemotherapy and immunomodulating treatment of patients with multiple myeloma].
Kraj M; Dmoszyńska A; Maj S; Kowalewski J; Rostkowska J; Pogłód R; Sokołowska B; Mendek-Czajkowska E; Kurowska M; Sokołowska U
Acta Haematol Pol; 1991; 22(1):4-20. PubMed ID: 1823965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
